ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis
INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news
ACR: Age at Psoriasis Onset Sets Course for Psoriatic Arthritis
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 12, 2019 Category: Pharmaceuticals Source Type: news
TREMFYA ® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies
Findings from the DISCOVER-1 and DISCOVER-2 studies are presented, for the first time, at the 2019 American College of Rheumatology and Association of Rheumatology Professionals Annual MeetingThese are the first Phase 3 results evaluating p19-specific IL-23 inhibition in active psoriatic arthritis (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 11, 2019 Category: Pharmaceuticals Source Type: news
Medical News Today: Can you prevent psoriatic arthritis?
It is impossible to know who will develop psoriatic arthritis, though it usually affects people who already have psoriasis. Learn about whether people can prevent psoriatic arthritis here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 4, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Medical News Today: What are the complications of psoriatic arthritis?
There are many possible complications of psoriatic arthritis, including uveitis, kidney disease, and depression. Learn about the risks and preventive steps here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
Medical News Today: What to know about distal interphalangeal joint pain
Distal interphalangeal joint pain is often due to osteoarthritis or psoriatic arthritis. Learn more about the causes and their symptoms in this article. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 29, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
Biologic DMARD Treatment and Bone Strength and Structure in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - October 17, 2019 Category: Orthopaedics Tags: CME Article Source Type: news
Effect of DMARDs on Bone Structure and Strength in PsA Effect of DMARDs on Bone Structure and Strength in PsA
In what ways might DMARD treatment impact bone structure and strength in patients with psoriatic arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis FDA OKs Ixekizumab (Taltz) for Active Ankylosing Spondylitis
The interleukin-17A inhibitor is now indicated for the treatment of adults with active ankylosing spondylitis, as well as for certain patients with plaque psoriasis and active psoriatic arthritis.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 26, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
Amgen To Acquire Otezla(R) For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Innovative Therapy Will Strengthen Amgen's Inflammation Portfolio for Patients Around the World
Acquisition Expected to Accelerate Growth and Enhance Value for Amgen Shareholders
Amgen to Host Call With Investors at 5 a.m. PT (8 a.m. ET)
THOUSAND ... Biopharmaceuticals, Acquisitions Amgen, Celgene, Otezla, apremilast, psoriasis, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2019 Category: Pharmaceuticals Source Type: news
Amgen to acquire Otezla ® for $13.4 billion in cash
Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. (Source: World Pharma News)
Source: World Pharma News - August 26, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues
Bulging Veins : What to Do About Varicose Veins
Dr. Stacey Missmer on Painful Periods in Teens
More Steps for Better Health
What is Psoriatic Arthritis?
Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - August 4, 2019 Category: Consumer Health News Source Type: news
Medical News Today: A guide to psoriatic arthritis medication
Medications can relieve the symptoms of psoriatic arthritis, slow disease progression, and reduce or prevent joint damage. We explore the current treatments and medication advances here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 24, 2019 Category: Consumer Health News Tags: Psoriatic Arthritis Source Type: news
August 2019
Period Problems : Fibroids, Endometriosis, and Other Issues
Bulging Veins : What to Do About Varicose Veins
Dr. Stacey Missmer on Painful Periods in Teens
More Steps for Better Health
What is Psoriatic Arthritis?
Urologic Diseases (Source: NIH News in Health)
Source: NIH News in Health - July 24, 2019 Category: Consumer Health News Source Type: news
